Display options
Cite
Bichara CDA, Queiroz MAF, da Silva Graça Amoras E, et al. Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil. Vaccines (Basel). 2021;9(10)doi: 10.3390/vaccines9101169.
Bichara, C. D. A., Queiroz, M. A. F., da Silva Graça Amoras, E., Vaz, G. L., Vallinoto, I. M. V. C., Bichara, C. N. C., Amaral, I. P. C. D., Ishak, R., & Vallinoto, A. C. R. (2021). Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil. Vaccines, 9(10), . https://doi.org/10.3390/vaccines9101169
Bichara, Carlos David Araújo, et al. "Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil." Vaccines vol. 9,10 (2021). doi: https://doi.org/10.3390/vaccines9101169
Bichara CDA, Queiroz MAF, da Silva Graça Amoras E, Vaz GL, Vallinoto IMVC, Bichara CNC, Amaral IPCD, Ishak R, Vallinoto ACR. Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil. Vaccines (Basel). 2021 Oct 12;9(10). doi: 10.3390/vaccines9101169. PMID: 34696277; PMCID: PMC8539673.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2021 Oct 12;9(10). doi: 10.3390/vaccines9101169.

Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil.

Vaccines

Carlos David Araújo Bichara, Maria Alice Freitas Queiroz, Ednelza da Silva Graça Amoras, Gergiane Lopes Vaz, Izaura Maria Vieira Cayres Vallinoto, Cléa Nazaré Carneiro Bichara, Isabella Pinheiro Costa do Amaral, Ricardo Ishak, Antonio Carlos Rosário Vallinoto

Affiliations

  1. Laboratory of Virology, Institute of Biological Sciences, Federal University of Pará (UFPA), Belém 66075-110, PA, Brazil.
  2. Amaral Costa Diagnostic Medicine, Belém 66055-050, PA, Brazil.
  3. Graduate Program in Biology of Infectious and Parasitic Agents, Institute of Biological Sciences, Federal University of Pará (UFPA), Belém 66075-110, PA, Brazil.
  4. Center for Biological and Health Sciences, School of Medicine, Pará State University (UEPA), Belém 66087-870, PA, Brazil.

PMID: 34696277 PMCID: PMC8539673 DOI: 10.3390/vaccines9101169

Abstract

The present study evaluated the frequency of seropositivity for anti-SARS-CoV-2 (S1 and S2) total antibodies and anti-SARS-CoV-2 (receptor binding domain-RBD-S1) neutralizing antibodies in individuals vaccinated with the immunizing agent Coronavac. This was a cross-sectional study involving 358 individuals divided into two groups. Group 1 consisted of 205 volunteers who were tested for anti-SARS-CoV-2 total antibodies; group 2 consisted of 153 individuals tested for the presence of anti-SARS-CoV-2 neutralizing antibodies. Seropositivity was greater than 70% in both groups, although 17.6% and 20.9% of individuals showed no neutralizing or total antibody reactivity, respectively. The frequency of anti-SARS-CoV-2 total antibodies displayed a significantly different distribution between the sexes but not according to age. The frequency of anti-SARS-CoV-2 neutralizing antibodies was 93.3% (95% CI 68.1-99.8) in the age group from 21 to 40 years but significantly decreased with advancing age, and was 76.2% (95% CI 52.8-91.8) for 41 to 60 years, 72.5% (95% CI 62.8-80.9) for 61 to 80 years, and 46.7% (95% CI 21.3-73.4) for >80 years. Our results reveal a high prevalence of anti-SARS-CoV-2 total antibodies and anti-SARS-CoV-2 neutralizing antibodies in individuals who received both doses of the Coronavac vaccine, suggesting a lower effectiveness of the humoral immune response among those older than 60 years of age, which might be associated with senescence of the immune system.

Keywords: COVID-19; Coronavac; SARS-CoV-2; antibody; vaccine

References

  1. Lancet Infect Dis. 2021 Jun;21(6):803-812 - PubMed
  2. Lancet. 2021 Jul 17;398(10296):213-222 - PubMed
  3. Science. 2020 May 29;368(6494):948-950 - PubMed
  4. Chem Commun (Camb). 2021 Feb 15;57(12):1474-1477 - PubMed
  5. Emerg Microbes Infect. 2021 Dec;10(1):1598-1608 - PubMed
  6. Cell. 2020 Jun 25;181(7):1489-1501.e15 - PubMed
  7. JAMA. 2021 Apr 6;325(13):1241-1243 - PubMed
  8. Vaccines (Basel). 2021 May 19;9(5): - PubMed
  9. Emerg Infect Dis. 2021 Jan;27(1): - PubMed
  10. PLoS Pathog. 2021 Mar 26;17(3):e1009420 - PubMed
  11. Hum Vaccin Immunother. 2021 Oct 3;17(10):3348-3354 - PubMed
  12. Acta Endocrinol (Buchar). 2020 Oct-Dec;16(4):522-523 - PubMed
  13. Womens Health (Lond). 2021 Jan-Dec;17:17455065211022262 - PubMed
  14. J Affect Disord. 2021 Aug 1;291:338-343 - PubMed
  15. JAMA. 2020 Nov 24;324(20):2095-2096 - PubMed
  16. Vaccines (Basel). 2021 Mar 05;9(3): - PubMed
  17. Cell Res. 2021 Jul;31(7):732-741 - PubMed
  18. Front Med (Lausanne). 2021 May 14;8:664179 - PubMed
  19. N Engl J Med. 2021 Jan 7;384(1):80-82 - PubMed
  20. JAMA. 2021 May 11;325(18):1896-1898 - PubMed

Publication Types

Grant support